home / stock / dmttf / dmttf news

DMTTF News and Press, Small Pharma From 05/25/23

Stock Information
Company Name: Small Pharma
Stock Symbol: DMTTF
Market: OTC
Website: smallpharma.com
Menu
DMTTF DMTTF Quote DMTTF Short DMTTF News DMTTF Articles DMTTF Message Board
Get DMTTF Alerts

News, Short Squeeze, Breakout and More Instantly...
DMTTF - Small Pharma Announces Significant Developments In Intellectual Property Portfolio

LONDON, May 25, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces an update...
DMTTF - Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology

LONDON, May 03, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, is pleased to announce th...

DMTTF - Small Pharma Announces Positive Six-month Data from Phase IIa Trial of SPL026

LONDON, April 04, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces positiv...

DMTTF - Small Pharma to Host Virtual Roundtable Event with Key Opinion Leaders in Psychiatry

LONDON, March 07, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces that it...
DMTTF - Small Pharma Announces Further Positive Data from SPL026 Phase IIa Trial in Major Depressive Disorder Strengthening Topline Efficacy Results

-Patients’ self-reported depression and wellbeing scores corroborate MADRS efficacy data -Statistically significant improvement in anxiety symptoms offers potential in new indications beyond depression LONDON, March 07, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT)...

DMTTF - Small Pharma to Present at Cowen's 43rd Annual Health Care Conference

LONDON, March 01, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, is pleased to announce ...

DMTTF - First Subject Dosed in Small Pharma's First-in-Human Phase I Clinical Trial with SPL028

SPL028 is a proprietary deuterated DMT candidate with multi-layered IP protection Phase I study will compare two routes of SPL028 administration; intravenous and intramuscular LONDON, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “...
DMTTF - Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue

New United States patents will provide further support for the Company’s proprietary position in a key jurisdiction United States grants will bring the Company’s total to 16 granted patents and over 90 applications pending LONDON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Sm...

DMTTF - Small Pharma GAAP EPS of -C$0.02

Small Pharma press release ( OTCQB:DMTTF ): Q3 GAAP EPS of -C$0.02. Cash on hand as of November 30, 2022 was C$22.7M Sedar Filings For further details see: Small Pharma GAAP EPS of -C$0.02

DMTTF - Small Pharma Reports Fiscal Third Quarter 2023 Highlights

Positive top-line results from Phase IIa trial of SPL026 in Major Depressive Disorder New SPL026 trials underway and screening commenced in the first in-human study of SPL028 LONDON, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the ...
Previous 10 Next 10